Catalyst Pharmaceuticals
(NASDAQ) CPRX
Catalyst Pharmaceuticals Financials at a Glance
Market Cap
$3.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$596.96M
Net Income (TTM)
$221.32M
EPS (TTM)
$1.74
P/E Ratio
18.09
Dividend
$0.00
Beta (Volatility)
0.98 (Low)
Dividend
$0.00
Beta (Volatility)
0.98 (Low)
Price
$31.49
Volume
43,620
Open
$31.48
Price
$31.49
Volume
43,620
Open
$31.48
Previous Close
$31.49
Daily Range
$31.47 - $31.49
52-Week Range
$19.05 - $32.56
Estimated Earnings Date
Aug 5, 2026
Dividend
$0.00
Beta (Volatility)
0.98 (Low)
Price
$31.49
Volume
43,620
Open
$31.48
Previous Close
$31.49
Daily Range
$31.47 - $31.49
52-Week Range
$19.05 - $32.56
Estimated Earnings Date
Aug 5, 2026
CPRX News
CPRX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Catalyst Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
182
CEO
Richard John Daly, MBA
Website
www.catalystpharma.comHeadquarters
Coral Gables, FL 33134, US
CPRX Financials
Key Financial Metrics (TTM)
Gross Margin
82.32%
Operating Margin
44.83%
Net Income Margin
37.08%
Return on Equity
23.65%
Return on Capital
26.93%
Return on Assets
19.29%
Earnings Yield
5.53%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$3.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
122.42M
Volume
43.62K
Avg. Volume
2.39M
Financials (TTM)
Gross Profit
$491.44M
Operating Income
$267.64M
EBITDA
$334.72M
Operating Cash Flow
$208.21M
Capital Expenditure
-$85.00K
Free Cash Flow
$208.13M
Cash & ST Invst.
$755.86M
Total Debt
$2.68M
Catalyst Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$149.39M
+5.6%
Gross Profit
$125.21M
+1.4%
Gross Margin
83.82%
N/A
Market Cap
$3.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$21.28M
N/A
Employees
181
N/A
Net Income
$63.73M
+12.3%
EBITDA
$94.08M
+16.5%
Quarterly Fundamentals
Total Cash
$755.86M
+30.2%
Total Debt
$2.68M
-13.3%
Accounts Receivable
$131.31M
+81.7%
Inventory
$34.93M
+76.6%
Long Term Debt
$2.24M
-16.6%
Short Term Debt
$446.00K
+8.8%
Return on Assets
19.29%
N/A
Return on Invested Capital
26.36%
N/A
Free Cash Flow
$59.56M
-0.8%
Operating Cash Flow
$59.59M
-0.8%